ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$16.53 USD
+0.11 (0.67%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $16.54 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth D Momentum A VGM
Balance Sheet
Fiscal Year End for ACADIA Pharmaceuticals Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 439 | 417 | 521 | 632 | 697 |
Receivables | 102 | 63 | 65 | 50 | 38 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 36 | 7 | 8 | 10 | 6 |
Other Current Assets | 39 | 21 | 24 | 26 | 19 |
Total Current Assets | 616 | 508 | 618 | 718 | 760 |
Net Property & Equipment | 5 | 6 | 8 | 9 | 3 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 5 | 5 | 6 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 65 | 0 | 0 | 1 | 3 |
Deposits & Other Assets | 6 | 13 | 10 | 7 | 8 |
Total Assets | 749 | 588 | 700 | 783 | 783 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 18 | 13 | 7 | 8 | 7 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 237 | 113 | 89 | 97 | 68 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 254 | 126 | 96 | 106 | 75 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 15 | 9 | 7 | 5 | 3 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 317 | 187 | 159 | 156 | 84 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,863 | 2,771 | 2,695 | 2,613 | 2,403 |
Retained Earnings | -2,431 | -2,370 | -2,154 | -1,986 | -1,704 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 432 | 400 | 541 | 627 | 699 |
Total Liabilities & Shareholder's Equity | 749 | 588 | 700 | 783 | 783 |
Total Common Equity | 432 | 400 | 541 | 627 | 699 |
Shares Outstanding | 164.10 | 161.90 | 160.70 | 158.90 | 154.00 |
Book Value Per Share | 2.63 | 2.47 | 3.37 | 3.95 | 4.54 |
Fiscal Year End for ACADIA Pharmaceuticals Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 501 | 471 | 439 | 346 | 375 |
Receivables | 110 | 100 | 102 | 95 | 84 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 72 | 62 | 36 | 21 | 9 |
Other Current Assets | 46 | 43 | 39 | 38 | 24 |
Total Current Assets | 729 | 675 | 616 | 499 | 493 |
Net Property & Equipment | 4 | 4 | 5 | 5 | 5 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 15 | 5 | 5 | 5 | 5 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 108 | 110 | 65 | 67 | 68 |
Deposits & Other Assets | 6 | 6 | 6 | 6 | 19 |
Total Assets | 914 | 855 | 749 | 633 | 643 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 20 | 19 | 18 | 12 | 19 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 318 | 311 | 237 | 197 | 169 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 338 | 331 | 254 | 210 | 188 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 12 | 15 | 13 | 9 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 397 | 391 | 317 | 270 | 247 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,898 | 2,879 | 2,863 | 2,839 | 2,808 |
Retained Earnings | -2,381 | -2,414 | -2,431 | -2,477 | -2,411 |
Other Equity | 0 | 0 | 0 | 0 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 517 | 464 | 432 | 362 | 396 |
Total Liabilities & Shareholder's Equity | 914 | 855 | 749 | 633 | 643 |
Total Common Equity | 517 | 464 | 432 | 362 | 396 |
Shares Outstanding | 165.20 | 165.20 | 164.10 | 164.10 | 163.70 |
Book Value Per Share | 3.13 | 2.81 | 2.63 | 2.21 | 2.42 |